Publications by the researcher in collaboration with NATO APTSIAURI (28)

2024

  1. Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer

    Journal for immunotherapy of cancer, Vol. 12, Núm. 10

2022

  1. Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer

    Pharmaceutics, Vol. 14, Núm. 3

2021

  1. CRC: A Darwinian model of cellular immunoselection

    Foundations of Colorectal Cancer (Elsevier), pp. 529-541

  2. Copy neutral loh affecting the entire chromosome 6 is a frequent mechanism of hla class i alterations in cancer

    Cancers, Vol. 13, Núm. 20

  3. HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy

    Cellular and Molecular Immunology, Vol. 18, Núm. 3, pp. 556-565

  4. Tumor escape phenotype in bladder cancer is associated with loss of HLA class I expression, T-cell exclusion and stromal changes

    International Journal of Molecular Sciences, Vol. 22, Núm. 14

2019

  1. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer

    Annals of Surgical Oncology, Vol. 26, Núm. 8, pp. 2631-2639

2018

  1. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15

    Immunogenetics, Vol. 70, Núm. 10, pp. 647-659

  2. HLA class I loss and PD-L1 expression in lung cancer: Impact on T-cell infiltration and immune escape

    Oncotarget, Vol. 9, Núm. 3, pp. 4120-4133

  3. The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses

    Current Opinion in Immunology, Vol. 51, pp. 123-132

2017

  1. Rejection versus escape: the tumor MHC dilemma

    Cancer Immunology, Immunotherapy, Vol. 66, Núm. 2, pp. 259-271

  2. The escape of cancer from T cell-mediated immune surveillance: HLA class I loss and tumor tissue architecture

    Vaccines, Vol. 5, Núm. 1

2016

  1. Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance

    Cancer Immunology, Immunotherapy, Vol. 65, Núm. 1, pp. 47-59

2014

  1. Adenovirus expressing β2-microglobulin recovers HLA class i expression and antitumor immunity by increasing T-cell recognition

    Cancer Gene Therapy, Vol. 21, Núm. 8, pp. 317-332

  2. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma

    International Journal of Cancer, Vol. 134, Núm. 1, pp. 102-113

2013

  1. MHC class i antigens and the tumor microenvironment

    The Tumor Immunoenvironment (Springer Netherlands), pp. 253-286

2009

  1. Efficient recovery of HLA class i expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: Implications for cancer immunotherapy

    Scandinavian Journal of Immunology, Vol. 70, Núm. 2, pp. 125-135

  2. HLA and melanoma: Multiple alterations in HLA class i and II expression in human melanoma cell lines from ESTDAB cell bank

    Cancer Immunology, Immunotherapy, Vol. 58, Núm. 9, pp. 1507-1515

2008

  1. Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines

    Cancer Immunology, Immunotherapy, Vol. 57, Núm. 5, pp. 719-729

  2. HLA class I expression, tumor escape and cancer progression

    Current Cancer Therapy Reviews, Vol. 4, Núm. 2, pp. 105-110